CN1202170A - 用作iv型磷酸二酯酶抑制剂的喹啉衍生物 - Google Patents

用作iv型磷酸二酯酶抑制剂的喹啉衍生物 Download PDF

Info

Publication number
CN1202170A
CN1202170A CN96198305A CN96198305A CN1202170A CN 1202170 A CN1202170 A CN 1202170A CN 96198305 A CN96198305 A CN 96198305A CN 96198305 A CN96198305 A CN 96198305A CN 1202170 A CN1202170 A CN 1202170A
Authority
CN
China
Prior art keywords
benzo
methyl
compound
quinoline
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96198305A
Other languages
English (en)
Chinese (zh)
Inventor
R·伦德
E·伯姆博维拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1202170A publication Critical patent/CN1202170A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN96198305A 1995-11-14 1996-11-13 用作iv型磷酸二酯酶抑制剂的喹啉衍生物 Pending CN1202170A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523267.4A GB9523267D0 (en) 1995-11-14 1995-11-14 Organic compounds
GB9523267.4 1995-11-14

Publications (1)

Publication Number Publication Date
CN1202170A true CN1202170A (zh) 1998-12-16

Family

ID=10783856

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96198305A Pending CN1202170A (zh) 1995-11-14 1996-11-13 用作iv型磷酸二酯酶抑制剂的喹啉衍生物

Country Status (17)

Country Link
EP (1) EP0873338A1 (cs)
JP (1) JPH11515000A (cs)
KR (1) KR19990067574A (cs)
CN (1) CN1202170A (cs)
AU (1) AU7570996A (cs)
BR (1) BR9611504A (cs)
CA (1) CA2235126A1 (cs)
CO (1) CO4770973A1 (cs)
CZ (1) CZ149498A3 (cs)
GB (1) GB9523267D0 (cs)
HU (1) HUP9903492A3 (cs)
MX (1) MX9803839A (cs)
PE (1) PE17598A1 (cs)
PL (1) PL326636A1 (cs)
SK (1) SK63998A3 (cs)
TR (1) TR199800851T2 (cs)
WO (1) WO1997018208A1 (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112423589A (zh) * 2018-06-24 2021-02-26 安道麦阿甘有限公司 制备氯甲喹啉酸的方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
KR20040007583A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
JP2006347936A (ja) * 2005-06-15 2006-12-28 Bayer Cropscience Ag 殺虫性ベンズアニリド類
US8394829B2 (en) 2010-05-10 2013-03-12 Gilead Sciences, Inc. Bi-functional quinoline analogs
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112423589A (zh) * 2018-06-24 2021-02-26 安道麦阿甘有限公司 制备氯甲喹啉酸的方法
CN112423589B (zh) * 2018-06-24 2023-03-10 安道麦阿甘有限公司 制备氯甲喹啉酸的方法

Also Published As

Publication number Publication date
WO1997018208A1 (en) 1997-05-22
KR19990067574A (ko) 1999-08-25
EP0873338A1 (en) 1998-10-28
HUP9903492A2 (en) 2000-07-28
CA2235126A1 (en) 1997-05-22
BR9611504A (pt) 1999-03-02
TR199800851T2 (xx) 1998-08-21
JPH11515000A (ja) 1999-12-21
GB9523267D0 (en) 1996-01-17
CO4770973A1 (es) 1999-04-30
AU7570996A (en) 1997-06-05
PL326636A1 (en) 1998-10-12
MX9803839A (es) 1998-09-30
CZ149498A3 (cs) 1998-08-12
SK63998A3 (en) 1998-10-07
PE17598A1 (es) 1998-04-06
HUP9903492A3 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
CN110088105B (zh) Jak家族激酶的小分子抑制剂
JP6506836B2 (ja) Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
US20260049095A1 (en) Deuterated stat3 degraders and uses thereof
US20070149547A1 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
AU2014234909B2 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
US7557134B2 (en) N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV1 receptor ligands
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
TW200900058A (en) N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic application
JP6387361B2 (ja) ピリジン−４−イル誘導体
KR102894755B1 (ko) 헤테로사이클로로 치환된 융합 γ-카르볼린 유도체, 이의 제조 방법, 중간체 및 용도
JP2022506898A (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物
CN103097367A (zh) 苯丙酸化合物、其制备方法及其医药用途
JP2022518260A (ja) Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物
KR19990067574A (ko) 유형 ⅳ 포스포디에스테라제 억제제로서의 퀴놀린 유도체
CN108191857B (zh) 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
TW201412732A (zh) 二氫嘧啶衍生物的晶型
CN1649843A (zh) 新查耳酮衍生物及其应用
CN1100301A (zh) 用于神经保护的药物
EP4735422A1 (en) Substituted cyclic compounds and methods of treating phenylketonuria and other amino acidurias
CN111848627A (zh) 二氢嘧啶类化合物及其在药物中的应用
TWI374878B (en) Phenanthrenone compounds, compositions and methods
EP3964509B1 (en) Compound containing fused ring, use thereof and pharmaceutical composition containing same
US20240076296A1 (en) Thiazole derivatives for therapeutic use
TWI811901B (zh) 一種嘧啶甲醯胺類化合物及其應用
KR20200030466A (ko) 7-하이드록시-4H-티에노[3,2-b]피리딘-5-온 유도체 및 그의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication